Militia Long/Short Equity ETF(ORR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ORR Militia Long/Short Equity ETF

盘后交易 05-26 19:02:41 EDT

36.41

+0.19

+0.52%

盘后36.41

+0.000.00%

16:10 EDT

最高36.50	最低36.07	成交量9.83万
今开36.20	昨收36.22	日振幅1.19%
总市值3.70亿	流通市值3.70亿	总股本1,015万
成交额357.33万	换手率0.97%	流通股本1,015万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":36.41,"timestamp":1779825600000,"preClose":36.22,"halted":0,"volume":98271,"hourTrading":{"tag":"盘后","latestPrice":36.41,"preClose":36.41,"latestTime":"16:10 EDT","volume":11,"amount":400.51,"timestamp":1779826205350,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.005245720596355542,"floatShares":10150000,"shares":10150000,"eps":0,"marketStatus":"盘后交易","change":0.19,"latestTime":"05-26 19:02:41 EDT","open":36.2,"high":36.5,"low":36.0701,"amount":3573256,"amplitude":0.011869,"askPrice":36.4,"askSize":20,"bidPrice":33.03,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779840000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":36.22,"sharesOutstanding":12720000,"nav":36.35,"aum":368952500,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":36.41,"preClose":36.41,"latestTime":"16:10 EDT","volume":11,"amount":400.51,"timestamp":1779826205350,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.857263,"impliedVol":0.2526,"impliedVolPercentile":0.9375},"requestUrl":"/m/hq/s/ORR","defaultTab":"news","newsList":[{"id":"2627491097","title":"核药“狂飙”：2026年中外巨头激战300亿美元蓝海","url":"https://stock-news.laohu8.com/highlight/detail?id=2627491097","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627491097?lang=zh_cn&edition=full","pubTime":"2026-04-14 12:54","pubTimestamp":1776142440,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛2026年的春天，核药赛道没有一丝“倒春寒”的迹象。4月中旬，两则消息几乎同时引爆了全球核医学圈。一则是关于“中国原创”的崛起：百洋医药集团孵化企业瑞迪奥研发的99mTc-3PRGD2（吉伦泰）正式获批，这是全球首个用于SPECT显像的广谱肿瘤显像剂，打破了PET技术近30年的垄断。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704207863.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704207863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4161","ORR","CR","HCC","BK4006","RDC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624601597","title":"营收同比下降33.8%，基石药业押注三抗管线进展如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624601597","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624601597?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:50","pubTimestamp":1775040648,"startTime":"0","endTime":"0","summary":"继2024年上半年首次实现盈利、全年财务业绩持续改善后，基石药业（2616.HK）2025年业绩再度下滑。年报显示，公司2025年实现收入2.7亿元，同比下降33.8%；年内亏损扩大至4.37亿元，较2024年的0.91亿元亏损增加3.46亿元。在业绩承压的背景下，基石药业同步披露了PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新开发进展及I/II期关键临床数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013692073178.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013692073178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU0053666078.USD","ORR","LU0210528500.USD","BK4588","BK4107","LU2487616109.SGD","L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623539793","title":"科赛优®在华获批用于治疗伴有症状、无法手术的丛状神经纤维瘤的1型神经纤维瘤病（NF1-PN）儿童及成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2623539793","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623539793?lang=zh_cn&edition=full","pubTime":"2026-03-30 15:46","pubTimestamp":1774856760,"startTime":"0","endTime":"0","summary":"成为国内首个且唯一*获批用于3岁及3岁以上该患者人群的治疗药物 上海2026年3月30日 /美通社/ -- 阿斯利康宣布，中国国家药品监督管理局已正式批准科赛优，一种选择性、口服MEK抑制剂，用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤的1型神经纤维瘤病儿童及成人患者的治疗[1]。司美替尼已在美国、欧盟、日本、中国及其他国家/地区获批，用于治疗特定伴有症状且无法手术切除PN的 NF1 儿童患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4922084_ZH22084_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0320765992.SGD","LU1829250122.USD","LU2417539215.USD","BK4007","BK4585","LU2462157665.USD","AZN","BK4588","LU0889565916.HKD","LU2456880835.USD","LU0058720904.USD","BK4096","PN","BK4568","ORR","LU0289739699.SGD","IE00B3T34201.USD","LU2236285917.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618995755","title":"Pan-KRAS赛道的新变量：JAB-23E73的胰腺癌ORR 38.5%背后的估值差","url":"https://stock-news.laohu8.com/highlight/detail?id=2618995755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618995755?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:20","pubTimestamp":1773192006,"startTime":"0","endTime":"0","summary":"Pan-KRAS赛道最近披露了一组很值得细看的数据。加科思公布了JAB-23E73在胰腺癌患者中的一期研究结果。目前披露的JAB-23E73安全性数据来自42例患者。RMC-6236的血液及肝肾毒性三级治疗相关不良事件为4%-7%，综合来看JAB-23E73安全性更优。JAB-23E73在160mg以上治疗组中，在可评估的13例KRAS突变胰腺癌患者中，有2例是二线治疗，剩下11例都是三线或三线以上的患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01167","ORR","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618987798","title":"达唯珂折戟，创新药研发安全红线再敲警钟","url":"https://stock-news.laohu8.com/highlight/detail?id=2618987798","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618987798?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:14","pubTimestamp":1773105251,"startTime":"0","endTime":"0","summary":"达唯珂由法国药企益普生旗下Epizyme开发，为全球同类首创的EZH2甲基转移酶抑制剂。达唯珂是全球首个且唯一获批用于滤泡性淋巴瘤的口服EZH2抑制剂。此次产品撤市、相关临床试验全面终止后，该细分领域精准治疗方案的空白将再次凸显，临床未满足需求亟待新一代创新药填补。2025年4月，公司以6.085亿美元现金出售上海和黄药业45%股权，仅保留5%股权，全面聚焦创新药研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310091707a45cda1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310091707a45cda1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HCM","LU2065731478.USD","ES","IE00BMG7P694.USD","BK4548","LU1228905540.USD","BK4081","LU1880398471.USD","LU0963586101.USD","BR","BK4588","BK4006","IE00BMG7P587.USD","LU1880398554.USD","BK4195","LU0545562505.USD","LU1883839398.USD","LU1228905037.USD","IE00B29SXL02.USD","LU2449327464.USD","IE0031619046.USD","IE00B19Z4B17.USD","IE00BMG7P819.SGD","LU0390134368.USD","BK4226","IE0009354923.USD","IE00BMQBXF63.USD","IE00BMG7P926.USD","IE00BZ18W340.USD","BK4531","BK4211","ORR","LU1803068623.USD","BK4106","CRS","IE0034235188.USD","BK4585","IE00BZ18W456.USD","IE00B66KJ199.SGD","LU2637428348.USD","PFS","IE00B29SXK94.USD","BK4007","BK4187","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613764020","title":"78亿美金，跨国药企达成闪电并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2613764020","media":"药圈观察局","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613764020?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:03","pubTimestamp":1771848202,"startTime":"0","endTime":"0","summary":"2023年6月，因一名患者死亡，FDA暂停了anito-cel的关键II期临床试验。然而，仅两个月后，FDA经审查解除了搁置，试验重回正轨。同年11月，Kite进一步扩大合作，支付2.85亿美元以获得Arcellx另一条管线ACLX-001的权益，并将对Arcellx的股权投资增至2亿美元，持股比例达到约13%。其市值在不到三年内从不足4亿美元飙升至收购前的数十亿美元，堪称“十倍股”。据悉，此次收购的灵魂是Arcellx的两大核心资产。市场方面，多发性骨髓瘤CAR-T市场预计在2030年达到120亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602232009079541ac53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602232009079541ac53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","IE00B3T34201.USD","LU0965508806.USD","IE00B19Z3B42.SGD","LU1571399168.USD","LU2324357040.USD","IE0002270589.USD","BK4588","LU0122379950.USD","ORR","LU0289739699.SGD","LU1061106388.HKD","GILD","LU2089984988.USD","LU1037948897.HKD","BK4550","CVR","LU1674673428.USD","LU1057294990.SGD","BK4578","LU1066051498.USD","LU1066053197.SGD","BK4566","SG9999015945.SGD","SG9999015986.USD","IE00BZ1G4Q59.USD","SG9999015952.SGD","LU0882574055.USD","LU1778281490.HKD","BK4139","LU0889565916.HKD","BK4585","BK4568","LU0058720904.USD","LU1674673691.USD","LU0114720955.EUR","IE00B19Z3581.USD","LU1037948541.HKD","LU0234570918.USD","LU2468319806.SGD","LU0823416689.USD","BK4583","LU0965509010.AUD","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU2087621335.USD","LU0861579265.USD","LU0965509283.SGD","LU0109394709.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠单抗胃癌新适应证获批，填补临床治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605989254?lang=zh_cn&edition=full","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4097","BK4211","ORR","PFS","BK4080","ADC","BK4231","OS","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605495703","title":"优赫得®在华获批治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605495703?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CSCO","LU1244550494.USD","IE00BFMHRM44.USD","BK4579","LU1880398554.USD","LU2237443622.USD","LU2506952097.USD","OS","BK4097","LU0109394709.USD","IE000M9KFDE8.USD","BK4612","ORR","LU1929549753.HKD","LU2237443382.USD","AZN","LU0234572021.USD","LU1244550577.SGD","BK4588","LU1066051498.USD","LU2247934214.USD","LU1571399168.USD","LU0868494617.USD","BK4195","LU2506951875.HKD","LU1196500208.SGD","LU2506951958.HKD","LU2417539215.USD","SG9999015978.USD","LU1066053197.SGD","LU0792757196.USD","BK4527","LU2462157665.USD","LU0320765992.SGD","LU1894683348.USD","BK4231","LU1046421795.USD","LU1221951046.USD","SG9999001440.SGD","LU2237443895.HKD","IE00BKVL7J92.USD","ADC","BK4080","LU1880398471.USD","BK4560","PFS","LU1221951129.SGD","LU2237443549.SGD","SG9999015945.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601490365","title":"ORR高达89.5%！智翔金泰BCMA/CD3双抗申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601490365","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601490365?lang=zh_cn&edition=full","pubTime":"2026-01-08 19:01","pubTimestamp":1767870060,"startTime":"0","endTime":"0","summary":"1月8日，智翔金泰宣布双抗药物GR1803的附条件上市申请已获得国家药监局受理，用于治疗既往至少接受过三线治疗的复发或难治性多发性骨髓瘤成人患者。GR1803是智翔金泰自主研发的一款BCMA/CD3双抗药物，其结合BCMA的亲和力较结合CD3的亲和力高两个数量级。2025年11月，智翔金泰在ASH 2025年会上公布了GR1803治疗R/R MM的I期研究数据。结果显示，在至少接受了一次疗效评估的57例患者中，客观缓解率为89.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-08/doc-inhfqyhi5239845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688443","ORR","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595412750","title":"君赛生物：聚焦实体瘤“免清淋”突破，GC101预计2026年提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2595412750","media":"新浪科技","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595412750?lang=zh_cn&edition=full","pubTime":"2025-12-30 10:41","pubTimestamp":1767062460,"startTime":"0","endTime":"0","summary":"新浪科技讯 12月30日上午消息，日前，聚焦实体瘤创新细胞疗法与创新药开发的上海君赛生物股份有限公司 正式向港交所递交招股书，拟依据港股18A章登陆生物科技板块。　　目前，GC101用于治疗黑色素瘤的临床试验正在开展关键II期临床试验，预计将于2026年提交生物制品许可申请；GC101用于治疗非小细胞肺癌的临床管线目前处于Ib期临床。　　按照计划，GC101预计2026年提交上市申请，若成功获批，将成为国内首个上市的TIL疗法。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/newstock/2025-12-30/doc-inhepszw4394800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","BK4505","ORR","TIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593176440","title":"多个新药或新适应症获FDA批准，涉及肿瘤、肥胖、肺纤维化等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2593176440","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593176440?lang=zh_cn&edition=full","pubTime":"2025-12-24 09:16","pubTimestamp":1766538973,"startTime":"0","endTime":"0","summary":"近日，多个创新药或新适应症获美国食品药品监督管理局批准，涉及罗氏、诺和诺德、勃林格殷格翰等。这些新药覆盖肿瘤、肥胖、肺纤维化等多个治疗领域，为患者带来了新的治疗选择。此次FDA批准基于关键性3期FIBRONEER-ILD临床试验结果，数据显示Jascayd可有效减缓PPF患者的肺功能下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224091748a6c7f4a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224091748a6c7f4a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CR","ORR","NVO","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590394122","title":"新股前瞻|布局TCE肿瘤疗法千亿蓝海，时迈药业能否博得市场青睐？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590394122?lang=zh_cn&edition=full","pubTime":"2025-12-09 13:05","pubTimestamp":1765256702,"startTime":"0","endTime":"0","summary":"近日，又一创新药企正式向港交所提交上市申请。在此背景下，作为一家专注于实体瘤TCE疗法、且具备多款全球前列临床管线的企业，时迈药业的上市进程亦自然备受瞩目。布局TCE疗法 四款创新药物处于临床阶段智通财经APP了解到，时迈药业目前仍处于临床研发阶段，并无产品商业化。根据时迈药业招股书披露，当前仅有两款用于实体瘤的TCE药物获得全球批准，市场存在大量空白，这为具备相关布局能力的创新药企提供了结构性机遇。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK4588","BK4187","BK4080","LU0053666078.USD","IE00B19Z4B17.USD","L","BK4585","IE00B7SZL793.SGD","IE0031619046.USD","BK4006","IE00B66KJ199.SGD","LU0963586101.USD","BK4107","LU2065731478.USD","CRS","LU2487616109.SGD","ADC","LU0210528500.USD","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590451393","title":"吉利德Anito-cel 神经毒性低，2年多发性骨髓瘤生存率高 | ASH25","url":"https://stock-news.laohu8.com/highlight/detail?id=2590451393","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590451393?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:58","pubTimestamp":1765166299,"startTime":"0","endTime":"0","summary":"在ASH 2025年会上，吉利德旗下Kite Pharma公布Anito-cel在iMMagine-1 II期试验中的更新数据，该靶向BCMA的CAR-T疗法在复发/难治性多发性骨髓瘤患者中显示96% ORR、74% sCR/CR率、95% MRD阴性率，中位随访15.9个月，缓解持续。III期iMMagine-3试验正在招募中，该研究将Anito-cel与标准治疗比较，预计2026年获得数据；该药物获FDA快速通道、孤儿药和RMAT资格。ICANS 发生率为 8%，其中 1 例为 3 级；其余均为 2 级或更低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208144817a43ac231&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B3T34201.USD","ORR","SG9999015978.USD","LU0889565916.HKD","LU1674673691.USD","BK4568","ASH","BK4187","IE00B7SZL793.SGD","CRS","LU0882574055.USD","BK4588","SG9999015945.SGD","SG9999015952.SGD","LU1430594728.SGD","IE00BKVL7J92.USD","BK4195","SG9999015986.USD","KOL","BK4578","LU0234570918.USD","IE0002270589.USD","BK4550","LU0320765992.SGD","BK4566","BK4097","BK4109","LU1585245621.USD","LU1571399168.USD","LU1778281490.HKD","IE00B19Z3581.USD","PFS","LU1066051498.USD","LU0109394709.USD","LU0289739699.SGD","IE00B19Z4B17.USD","GILD","LU0823416689.USD","CR","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IE00B66KJ199.SGD","OS","LU1839511570.USD","IE00B19Z3B42.SGD","BK4585","BK4532","LU1674673428.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518213795","title":"KRAS G12D先驱都扛不住了","url":"https://stock-news.laohu8.com/highlight/detail?id=2518213795","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518213795?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:17","pubTimestamp":1741594679,"startTime":"0","endTime":"0","summary":"热度持续攀升的KRAS G12D领域，却不断传出糟糕的消息。3月5日，据外媒消息，BMS已经放弃开发KRAS G12D抑制剂MRTX1133，原因是前景堪忧。这并非KRAS G12D赛道的第一个坏消息。如今，随着又一位重磅选手折戟，无疑给KRAS G12D领域敲响了警钟，尤其是对于处在跟随阶段的国内药企来说。很显然，这些国内跟随的选手需要进一步审视其KRAS G12D分子的结构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/252604","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512794661","title":"东方亮，西方不亮：出海管线之殇","url":"https://stock-news.laohu8.com/highlight/detail?id=2512794661","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512794661?lang=zh_cn&edition=full","pubTime":"2025-02-19 17:18","pubTimestamp":1739956689,"startTime":"0","endTime":"0","summary":"海外的临床结果，能否达到中国早期试验的承诺？但很遗憾，结果并不是那么让人满意。最新给出回答的是Corbus Pharmaceuticals。在ASCO泌尿生殖系统癌症研讨会上，Corbus公布了引进自石药集团的Nectin-4 ADC CRB-70第一个西方临床结果。数据公布后，Corbus盘中股价跌幅一度超15%。在该消息的影响下，Elevation单日股价暴跌63.37%。石药集团在中国开展的1期临床，初步ORR是28%；而Corbus在海外开展的1期临床，初步ORR是27%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/251165","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1521","01093","IE0008368742.USD","LU0501845795.SGD","IE00B031HY20.USD","LU1993786604.SGD","LU1152091168.USD","LU1951186391.HKD","BK1515","ORR","LU0140636845.USD","LU1960683339.HKD","LU0072913022.USD","LU1226287792.SGD","BK1191","LU0067412154.USD","LU1226287875.USD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","LU0880133367.SGD","LU1008478684.HKD","LU1226288170.HKD","LU1807302812.USD","LU1152091754.HKD","IE00BZ08YT58.USD","IE0008369823.USD","LU0326950275.SGD","IE00B543WZ88.USD","LU1226287529.USD","SG9999004220.SGD","LU1226288253.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512142249","title":"DLL3领域的中国时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2512142249","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512142249?lang=zh_cn&edition=full","pubTime":"2025-02-17 16:37","pubTimestamp":1739781474,"startTime":"0","endTime":"0","summary":"DLL3靶点研究开发已有超20年历史，该领域的FIC药物安进的CD3/DLL3双抗tarlatamab也已经获批上市。中国药企再一次将DLL3靶点的研发，推向了新一轮高潮。2023年11月至今，DLL3领域共有6起超1亿美元的交易，中国药企贡献了3例。这场围绕DLL3靶点的争夺战，正在成为中国创新药崛起的缩影。在DLL3靶点研发领域，引领发展的是海外科学家。从再鼎医药的临床数据公布，再到恒瑞医药、信达生物的接连出海，证明了中国药企在DLL3 ADC领域的搅局能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/250965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4006","IE00B19Z4B17.USD","ORR","CRS","LU2065731478.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","IE0031619046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504212978","title":"信达生物与奥赛康药业宣布第三代EGFR TKI 肺癌靶向药物奥壹新®（利厄替尼片）获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2504212978","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504212978?lang=zh_cn&edition=full","pubTime":"2025-01-17 08:00","pubTimestamp":1737072000,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年1月17日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司，与奥赛康药业今日联合宣布，第三代表皮生长因子受体酪氨酸激酶抑制剂靶向药物奥壹新的新药上市申请获中国国家药品监督管理局批准上市，用于既往经EGFR-TKI治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌成人患者治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4598259_ZH98259_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4195","ORR","BK1589","BK4211","BK1161","LU2328871848.SGD","PFS","PPI","IVBIY","LU1969619763.USD","BK1583","BK4570","LU2488822045.USD","01801","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":0.0114},{"period":"3month","weight":-0.0648},{"period":"6month","weight":0.1005},{"period":"1year","weight":0.2869},{"period":"ytd","weight":0.0603}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"NASDAQ","name":"Militia Long/Short Equity ETF","nameEN":"Militia Long/Short Equity ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Militia Long/Short Equity ETF(ORR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Militia Long/Short Equity ETF(ORR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Militia Long/Short Equity ETF,ORR,Militia Long/Short Equity ETF股票,Militia Long/Short Equity ETF股票老虎,Militia Long/Short Equity ETF股票老虎国际,Militia Long/Short Equity ETF行情,Militia Long/Short Equity ETF股票行情,Militia Long/Short Equity ETF股价,Militia Long/Short Equity ETF股市,Militia Long/Short Equity ETF股票价格,Militia Long/Short Equity ETF股票交易,Militia Long/Short Equity ETF股票购买,Militia Long/Short Equity ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Militia Long/Short Equity ETF(ORR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Militia Long/Short Equity ETF(ORR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}